PPIDT00067
Drug Information
| Name | Daptomycin |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB00080 |
| Type | small molecule |
| Indication | Daptomycin is indicated for the treatment of complicated skin and skin structure infections (cSSSI) in patients one year of age and older. It is also indicated for the treatment of _Staphylococcus aureus_ bloodstream infections (bacteremia) in patients one year of age and older, including in adult patients with right-sided infective endocarditis.[L32534] Daptomycin is not indicated for the treatment of pneumonia or left-sided infective endocarditis due to _S. aureus_. Use is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central).[L32534] As with all antibacterial drugs, it is strongly suggested to perform sufficient testing before treatment initiation in order to confirm an infection caused by susceptible bacteria. Failure to do so may result in suboptimal treatment, treatment failure, and the development of drug-resistant bacteria.[L32534] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| — | Intravenous |
350 mg
|
| Injection | Intravenous |
350 mg/350mg
|
| Injection, powder, for solution | Intravenous; Parenteral |
500 MG
|
| Powder, for solution | Intravenous |
500 mg / vial
|
| Solution | Intravenous |
500 mg
|
| Injection, solution | Intravenous |
500 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
500 mg/10mL
|
| Injection | Parenteral |
350 mg
|
| Injection | Parenteral |
500 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
500 mg
|
| Injection, powder, for solution | Intravenous |
350 MG
|
| Injection, powder, for solution | Intravenous |
500 MG
|
| Injection, powder, for solution | — |
350 MG
|
| Injection, powder, for solution | — |
500 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
35000000 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
50000000 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
350 mg/7mL
|
| Injection, powder, lyophilized, for solution | Intravenous |
50 mg/1mL
|
| Injection, powder, lyophilized, for suspension | Intravenous |
500 mg/20mL
|
| Injection, powder, for solution | Parenteral |
|
| Solution | Parenteral |
350 mg
|
| Solution | Parenteral |
500 mg
|
| Powder, for solution | Intravenous |
350 mg / vial
|
| — | Intravenous |
500 mg
|
| Injection | Intravenous |
500 mg
|
| Injection, solution | Intravenous |
1000 mg/100mL
|
| Injection, solution | Intravenous |
350 mg/50mL
|
| Injection, solution | Intravenous |
500 mg/50mL
|
| Injection, solution | Intravenous |
700 mg/100mL
|
| Injection, powder, for solution | Parenteral |
350 mg
|
| Injection, powder, for solution | Parenteral |
500 mg
|
| Solution | Intravenous |
350.000 mg
|
| Solution | Intravenous |
500.000 mg
|
| Injection, solution | Intravenous |
350 mg
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P0AC13 | folP | Dihydropteroate synthase | Escherichia coli (strain K12) | binder | Link |
| transporter | P08183 | ABCB1 | ATP-dependent translocase ABCB1 | Homo sapiens | substrate | Link |
| carrier | P02768 | ALB | Albumin | Homo sapiens | binder | Link |
| carrier | P02763 | ORM1 | Alpha-1-acid glycoprotein 1 | Homo sapiens | binder | Link |
| carrier | P01009 | SERPINA1 | Alpha-1-antitrypsin | Homo sapiens | binder | Link |
| carrier | P01130 | LDLR | Low-density lipoprotein receptor | Homo sapiens | binder | Link |
| carrier | P04278 | SHBG | Sex hormone-binding globulin | Homo sapiens | binder | Link |
| carrier | P02790 | HPX | Hemopexin | Homo sapiens | binder | Link |